The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being investigated in late-stage clinical trials for the manag...

Descripción completa

Detalles Bibliográficos
Autores principales: McNeel, Douglas G., Bander, Neil H., Beer, Tomasz M., Drake, Charles G., Fong, Lawrence, Harrelson, Stacey, Kantoff, Philip W., Madan, Ravi A., Oh, William K., Peace, David J., Petrylak, Daniel P., Porterfield, Hank, Sartor, Oliver, Shore, Neal D., Slovin, Susan F., Stein, Mark N., Vieweg, Johannes, Gulley, James L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5170901/
https://www.ncbi.nlm.nih.gov/pubmed/28031820
http://dx.doi.org/10.1186/s40425-016-0198-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5170901/
https://www.ncbi.nlm.nih.gov/pubmed/28031820
http://dx.doi.org/10.1186/s40425-016-0198-x

Ejemplares similares